JP2019530449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530449A5 JP2019530449A5 JP2019515991A JP2019515991A JP2019530449A5 JP 2019530449 A5 JP2019530449 A5 JP 2019530449A5 JP 2019515991 A JP2019515991 A JP 2019515991A JP 2019515991 A JP2019515991 A JP 2019515991A JP 2019530449 A5 JP2019530449 A5 JP 2019530449A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- antigen
- specific
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000427 antigen Substances 0.000 claims description 135
- 108091007433 antigens Proteins 0.000 claims description 135
- 102000036639 antigens Human genes 0.000 claims description 135
- 210000004027 cell Anatomy 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 116
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 88
- 210000000601 blood cell Anatomy 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 37
- 244000052769 pathogen Species 0.000 claims description 31
- 230000001717 pathogenic effect Effects 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 241000701022 Cytomegalovirus Species 0.000 claims description 9
- 108700028369 Alleles Proteins 0.000 claims description 8
- 208000008383 Wilms tumor Diseases 0.000 claims description 8
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 8
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 8
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 7
- 108091008048 CMVpp65 Proteins 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 5
- 230000001235 sensitizing effect Effects 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 102100033467 L-selectin Human genes 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 14
- 206010070834 Sensitisation Diseases 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022068256A JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399311P | 2016-09-23 | 2016-09-23 | |
| US62/399,311 | 2016-09-23 | ||
| PCT/US2017/052846 WO2018057823A1 (en) | 2016-09-23 | 2017-09-22 | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068256A Division JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530449A JP2019530449A (ja) | 2019-10-24 |
| JP2019530449A5 true JP2019530449A5 (enExample) | 2020-11-12 |
Family
ID=60117744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515991A Ceased JP2019530449A (ja) | 2016-09-23 | 2017-09-22 | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 |
| JP2022068256A Pending JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068256A Pending JP2022087340A (ja) | 2016-09-23 | 2022-04-18 | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10857182B2 (enExample) |
| EP (1) | EP3515461A1 (enExample) |
| JP (2) | JP2019530449A (enExample) |
| AR (1) | AR109707A1 (enExample) |
| AU (1) | AU2017330379B2 (enExample) |
| CA (1) | CA3037002A1 (enExample) |
| WO (1) | WO2018057823A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2859093A4 (en) * | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| AU2017330379B2 (en) | 2016-09-23 | 2023-07-13 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory T cells |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| AU2019268545A1 (en) * | 2018-05-18 | 2020-12-10 | The Council Of The Queensland Institute Of Medical Research | Adoptive T-cell therapy for CMV infection and CMV-associated diseases |
| TW202130807A (zh) * | 2019-10-28 | 2021-08-16 | 日商第一三共股份有限公司 | 具有ｃｄ４５ｒａ⁺及ｃｃｒ７⁺之細胞表面標誌的t細胞之製造方法 |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
| CN114578048B (zh) * | 2021-12-22 | 2023-08-08 | 重庆医科大学附属儿童医院 | 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒 |
| JP2025504968A (ja) * | 2022-01-27 | 2025-02-19 | 上海市第一人民医院 | サイトメガロウイルス抗原を標的とするｔｃｒおよびそれを発現するｔ細胞ならびに使用 |
| WO2024139780A1 (zh) * | 2022-12-26 | 2024-07-04 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
| US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
| US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7163685B2 (en) | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| EP2611905A4 (en) | 2010-09-01 | 2014-02-12 | Baylor College Medicine | EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF LOCOREGIONAL NANOPHARYNX CARCINOMA (NPC) |
| US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2015127190A1 (en) * | 2014-02-21 | 2015-08-27 | Argos Therapeutics, Inc. | Tscm cells and methods for use |
| AU2015343239B2 (en) | 2014-11-05 | 2021-06-03 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
| IL258935B2 (en) * | 2015-10-28 | 2024-08-01 | Life Tech As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
| AU2017330379B2 (en) | 2016-09-23 | 2023-07-13 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory T cells |
-
2017
- 2017-09-22 AU AU2017330379A patent/AU2017330379B2/en active Active
- 2017-09-22 EP EP17784722.5A patent/EP3515461A1/en active Pending
- 2017-09-22 CA CA3037002A patent/CA3037002A1/en active Pending
- 2017-09-22 JP JP2019515991A patent/JP2019530449A/ja not_active Ceased
- 2017-09-22 US US16/333,651 patent/US10857182B2/en active Active
- 2017-09-22 WO PCT/US2017/052846 patent/WO2018057823A1/en not_active Ceased
- 2017-09-22 AR ARP170102632A patent/AR109707A1/es unknown
-
2022
- 2022-04-18 JP JP2022068256A patent/JP2022087340A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530449A5 (enExample) | ||
| Edelson | Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation | |
| Brightman et al. | Harnessing neoantigen specific CD4 T cells for cancer immunotherapy | |
| Idoyaga et al. | Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A | |
| US11369668B1 (en) | Tumor cell vaccines | |
| Matsuzaki et al. | Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses | |
| Fong et al. | Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy | |
| ES2586206T3 (es) | Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T | |
| Harimoto et al. | Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells | |
| Sun et al. | Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma | |
| Timmerman, MD et al. | Dendritic cell vaccines for cancer immunotherapy | |
| JP2021192630A (ja) | 生体分子の免疫細胞への送達 | |
| Yoshikawa et al. | HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells | |
| Montico et al. | Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy | |
| CN111566201A (zh) | 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法 | |
| Ochi et al. | Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy | |
| CN103502439A (zh) | 用于抗原特异性t细胞增殖的方法 | |
| Dai et al. | PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines | |
| Cho et al. | An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells | |
| AU2006288348A1 (en) | Method for activation treatment of antigen-presenting cell | |
| Nchinda et al. | Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells | |
| Guo et al. | Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies | |
| Wang et al. | An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens | |
| Wu et al. | Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells |